Scarica l'app Stockscreener
18.31
4.19%
-0.80
Dopo l'orario di chiusura:
18.67
0.36
+1.97%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TNDM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$19.11
Aprire:
$18.77
Volume 24 ore:
1.59M
Relative Volume:
0.83
Capitalizzazione di mercato:
$1.27B
Reddito:
$1.03B
Utile/perdita netta:
$-94.55M
Rapporto P/E:
-13.07
EPS:
-1.4012
Flusso di cassa netto:
$-3.64M
1 W Prestazione:
-10.38%
1M Prestazione:
-19.73%
6M Prestazione:
-16.32%
1 anno Prestazione:
+48.02%
Intervallo 1D:
$18.09
$19.05
Intervallo di 1 settimana:
$18.09
$20.62
Portata 52W:
$11.46
$29.65
Tandem Diabetes Care Inc Stock (TNDM) Company Profile
Nome
Tandem Diabetes Care Inc
Settore
Industria
Telefono
858-366-6900
Indirizzo
12400 HIGH BLUFF DRIVE, San Diego, CA
Compare TNDM vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNDM
Tandem Diabetes Care Inc
|
18.31 | 1.33B | 1.03B | -94.55M | -3.64M | -1.4012 |
ABT
Abbott Laboratories
|
103.36 | 182.09B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.62 | 117.54B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
270.01 | 105.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.10 | 65.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.77 | 49.67B | 6.30B | 1.07B | 1.09B | 1.8406 |
Tandem Diabetes Care Inc Stock (TNDM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-19 | Aggiornamento | Truist | Hold → Buy |
| 2026-03-17 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2026-02-23 | Aggiornamento | Lake Street | Hold → Buy |
| 2026-02-20 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2026-01-27 | Ripresa | TD Cowen | Buy |
| 2025-12-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2025-10-21 | Ripresa | Stifel | Hold |
| 2025-09-08 | Iniziato | Oppenheimer | Outperform |
| 2025-08-12 | Aggiornamento | Citigroup | Sell → Neutral |
| 2025-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-07-09 | Downgrade | Citigroup | Neutral → Sell |
| 2025-06-16 | Iniziato | Truist | Hold |
| 2025-04-10 | Iniziato | Mizuho | Neutral |
| 2025-03-05 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-02-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-06 | Iniziato | Bernstein | Outperform |
| 2024-10-04 | Iniziato | Goldman | Neutral |
| 2024-10-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-08-22 | Iniziato | Morgan Stanley | Equal-Weight |
| 2024-08-08 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-30 | Iniziato | Redburn Atlantic | Buy |
| 2024-05-22 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-04-29 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-04-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-03-26 | Aggiornamento | Stifel | Hold → Buy |
| 2023-08-04 | Downgrade | Citigroup | Buy → Neutral |
| 2023-05-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-04-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-01-26 | Iniziato | Wolfe Research | Peer Perform |
| 2022-11-15 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-08-09 | Downgrade | Wells Fargo | Overweight → Underweight |
| 2022-03-02 | Ripresa | BofA Securities | Neutral |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Underweight |
| 2020-12-15 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-08-20 | Iniziato | Wells Fargo | Overweight |
| 2020-07-31 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-06 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-18 | Reiterato | Raymond James | Outperform |
| 2020-04-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-06 | Iniziato | Raymond James | Outperform |
| 2020-02-04 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-18 | Iniziato | Guggenheim | Buy |
| 2019-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2019-05-17 | Reiterato | BofA/Merrill | Neutral |
| 2019-05-13 | Iniziato | SVB Leerink | Outperform |
| 2019-03-08 | Iniziato | BMO Capital Markets | Outperform |
| 2019-03-05 | Reiterato | BofA/Merrill | Neutral |
| 2019-02-27 | Reiterato | Lake Street | Buy |
| 2018-11-21 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-09-26 | Reiterato | Dougherty & Company | Buy |
| 2018-09-26 | Reiterato | Piper Jaffray | Overweight |
Mostra tutto
Tandem Diabetes Care Inc Borsa (TNDM) Ultime notizie
Is Tandem Diabetes Care Inc (TNDM) a Bargain After 4.2% Drop? GF Value Says Undervalued - GuruFocus
Zacks Investment Research - גלובס
Why Did TNDM Stock Jump 5% After Hours Despite Q4 Earnings Miss? - Stocktwits
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now - Yahoo Finance
(TNDM) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
A Look at Tandem Diabetes Care Inc (TNDM) After 3.4% Decline -- GF Value $24.05 vs Price $20.56 - GuruFocus
Tandem Diabetes Care stock gains after recent rally in diabetes tech - ad-hoc-news.de
TANDEM DIABETES CARE INC (TNDM) Stock Chart - ChartMill
Tandem Diabetes Care (TNDM) Edges Higher to $21.49, Holding Above Key SupportGrowth ETF - vinanet.vn
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking - Sahm
Can PODD Sustain Growth After Its 2026 Guidance Reset and Q2 Beat? - TradingView
TNDM Initiated Coverage On by William Blair -- Rating Set to Out - gurufocus.com
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics - Benzinga
William Blair initiates Tandem Diabetes stock with outperform rating By Investing.com - Investing.com Nigeria
Tandem Diabetes (TNDM) Q2 2026 Earnings Call Transcript - AOL.com
How Tandem’s Q2 Loss and Pharmacy Pivot Will Impact Tandem Diabetes Care (TNDM) Investors - simplywall.st
Tandem (TNDM) Earnings Brief: Profit Per Share Clears Its Benchmark in the Current Update; Price Action: Shares Finish 6.63% Up at the CloseEarnings Season Preview - Vinanet
Tandem Diabetes Care CFO Leigh Vosseller Reports RSU Vesting Transactions on August 15, 2026 - Kalkine Media
Tandem Diabetes Care CEO John F. Sheridan Reports August 2026 RSU Vesting and Tax Withholding Details - Kalkine Media
Tandem Diabetes Care | 4: Statement of changes in beneficial ownership of securities-Officer Sheridan John F - Moomoo
Tandem Diabetes Care | 4: Statement of changes in beneficial ownership of securities-Officer Morrison Susan - Moomoo
Tandem Diabetes (TNDM) CFO vests RSUs as shares withheld for tax - Stock Titan
Tandem Diabetes (NASDAQ: TNDM) exec nets 475 shares after RSU vesting - Stock Titan
Tandem Diabetes (NASDAQ: TNDM) CEO vests 15,916 RSUs as shares withheld for tax - Stock Titan
Tandem Diabetes Care | 4: Statement of changes in beneficial ownership of securities-Officer Kyrillos Jean-Claude - Moomoo
Tandem Diabetes (NASDAQ: TNDM) CSO vests 3,014 RSUs, 1,618 withheld - Stock Titan
Tandem Diabetes (NASDAQ: TNDM) CLO RSUs vest, with shares withheld for taxes - Stock Titan
Tandem Diabetes (NASDAQ: TNDM) CTO withholds 1,277 shares to cover RSU taxes - Stock Titan
Tandem Diabetes (NASDAQ: TNDM) holder to sell 131 RSU shares - Stock Titan
Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi - Yahoo Finance
Tandem Diabetes Care Inc (TNDM) (Q2 2026) Earnings Call Highligh - GuruFocus
Tandem Diabetes Care Inc (TNDM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Renaissance Technologies LLC Purchases New Position in Tandem Diabetes Care, Inc. $TNDM - MarketBeat
Tandem Diabetes Care (NASDAQ:TNDM) Shares Cross Above 200-Day Moving AverageTime to Sell? - marketbeat.com
5 Must-Read Analyst Questions From Tandem Diabetes’s Q2 Earnings Call - Yahoo Finance
TNDM|Tandem Diabetes Care Inc|Price:22.617|Chg%:-0.513 - TradingKey
(TNDM) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Tandem Diabetes Care, Inc. (TNDM) Stock Forecasts - Yahoo Finance
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up - The Globe and Mail
Tandem Diabetes Care, Inc. (TNDM) Investor Outlook: Analyzing 25% Potential Upside with No Sell Ratings - DirectorsTalk Interviews
Tandem Diabetes Care Inc (TNDM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Why Tandem Diabetes (TNDM) Stock Is Trading Up Today - Yahoo Finance
TNDM Q2 Deep Dive: Pharmacy Channel Gains and Pipeline Execution Amid Margin Recovery - Yahoo Finance
Tandem Diabetes Care, Inc. (TNDM) Stock forecasts - Yahoo Finance UK
Why Tandem Diabetes Care (TNDM) Is Up 14.8% After Record Q2 Sales And PayGo Momentum - finance.yahoo.com
Tandem Diabetes Care (TNDM) Could Be 23% Below Fair Value After Q2 Results - Yahoo Finance
TNDM Maintained by Citigroup -- Price Target Raised to $21.00 - GuruFocus
Tandem Diabetes Care (NASDAQ:TNDM) Announces Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Deutsche Bank Adjusts Tandem Diabetes Care PT to $18 From $15.50, Maintains Hold Rating - Moomoo
Oppenheimer reiterates Tandem Diabetes stock rating on pharmacy gains By Investing.com - Investing.com South Africa
TNDM Maintained by RBC Capital -- Price Target Lowered to $26 - GuruFocus
Tandem Diabetes Care Inc Azioni (TNDM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.29%
0.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):